In addition to the parent chalcone SU086, the Hsp90 inhibitor 17-AAG (tanespimycin) and the multi-kinase inhibitor sorafenib (currently used to treat advanced HCC) were applied as positive control drugs. The gene discussed is HSP90AA1; the disease is hepatocellular carcinoma.